Accelerate Diagnostics, Inc. (AXDX) | Investment Case

1. Company Snapshot

1.a. Company Description

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East.The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk.

The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc.in December 2012.Accelerate Diagnostics, Inc.

was incorporated in 1982 and is headquartered in Tucson, Arizona.

Show Full description

1.b. Last Insights on AXDX

Accelerate Diagnostics' recent performance was negatively impacted by preliminary Q4 2024 results, which showed a decline in revenue and growth. The company announced a 12% decrease in revenue for the quarter, likely due to decreased demand for its diagnostic services. Additionally, the company's guidance for 2025 was lower than expected, further weighing on investor sentiment. The stock price may also be affected by the company's announcement that it will discontinue certain products and services, indicating a shift in its business strategy.

1.c. Company Highlights

Last Price	0.03
Change Percentage	0.00%
Open	0.08
Previous Close	0.03
Market Cap ( Millions)	1
Volume	13824707
Year High	2.09
Year Low	0.01
M A 50	0.6
M A 200	1.28

FCF Yield	-1830.17%
Dividend Yield	0.00%
ROE	77.07%
Debt / Equity	-118.80%
Net Debt / EBIDTA	-227.26%
Price To Book	-0.01
Price Earnings Ratio	-0.02
Price To FCF	-0.05
Price To sales	0.1
EV / EBITDA	-2.31

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Accelerate Diagnostics Files for Chapter 11 Protection and Agrees to Terms to Sell Substantially All Assets

May -08

Source: prnewswire.com

Accelerate Diagnostics Submits WAVE System and Gram-Negative Positive Blood Culture Menu to the FDA for 510(k) Clearance

Mar -21

Source: prnewswire.com

Accelerate Diagnostics Reports Fourth Quarter and Full-Year 2024 Financial Results

Mar -21

Source: prnewswire.com

Accelerate Diagnostics Announces Certain Preliminary Fourth Quarter and Full-Year 2024 Results

Jan -10

Source: prnewswire.com

Accelerate Diagnostics, Inc. (AXDX) Q3 2024 Earnings Call Transcript

Nov -09

Source: seekingalpha.com

Accelerate Diagnostics (AXDX) Reports Q3 Loss, Lags Revenue Estimates

Nov -07

Source: zacks.com

Accelerate Diagnostics Reports Third Quarter 2024 Financial Results

Nov -07

Source: prnewswire.com

Accelerate Diagnostics Scheduled Call to Review 2024 Third Quarter Results

Oct -25

Source: prnewswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (10.47%)

6. Segments

Accelerate Pheno

Expected Growth: 10.47%

Accelerate Pheno's 10.47% growth is driven by increasing adoption in hospitals and labs, expansion into new geographies, and growing demand for rapid diagnostic testing. Additionally, strategic partnerships, innovative product pipeline, and cost savings from operational efficiencies contribute to the company's accelerated growth.

Other

Expected Growth: 8.27%

Accelerate Diagnostics' 8.27% growth is driven by increasing adoption of its rapid diagnostic testing platform, particularly in the infectious disease segment. Growing demand for faster and accurate diagnostic results, coupled with expanding product offerings and strategic partnerships, contribute to the company's accelerated growth.

7. Detailed Products

Accelerate Pheno

Accelerate Pheno is a rapid, phenotypic antibiotic susceptibility testing (AST) system that provides accurate and actionable results in a matter of hours, enabling clinicians to make informed treatment decisions quickly.

Accelerate PhenoTest BC Kit

The Accelerate PhenoTest BC Kit is a rapid, phenotypic antibiotic susceptibility testing (AST) kit that provides accurate and actionable results in a matter of hours, enabling clinicians to make informed treatment decisions quickly.

Accelerate Arc Module

The Accelerate Arc Module is a modular, automated system that integrates with the Accelerate Pheno system to provide a comprehensive solution for rapid, phenotypic antibiotic susceptibility testing (AST) and microbial identification.

8. Accelerate Diagnostics, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

The threat of substitutes for Accelerate Diagnostics, Inc. is low due to the company's unique molecular diagnostic testing products and services, which are not easily substitutable.

Bargaining Power Of Customers

The bargaining power of customers for Accelerate Diagnostics, Inc. is medium, as the company's customers, such as hospitals and clinical laboratories, have some negotiating power due to their volume of purchases.

Bargaining Power Of Suppliers

The bargaining power of suppliers for Accelerate Diagnostics, Inc. is low, as the company is not heavily dependent on a few suppliers, and the suppliers do not have significant bargaining power.

Threat Of New Entrants

The threat of new entrants for Accelerate Diagnostics, Inc. is high, as the molecular diagnostic testing industry is attractive and has low barriers to entry, making it easier for new companies to enter the market.

Intensity Of Rivalry

The intensity of rivalry for Accelerate Diagnostics, Inc. is medium, as the company operates in a competitive industry with several established players, but the company's unique products and services help to differentiate it from its competitors.

9. SWOT Analysis

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

	Value
Debt Weight	207.50%
Debt Cost	6.62%
Equity Weight	-107.50%
Equity Cost	6.62%
WACC	6.62%
Leverage	-193.02%

11. Quality Control: Accelerate Diagnostics, Inc. passed 3 out of 9 key points

Strong Liquidity

Low Debt

Strong Interest Coverage

Healthy Cash Flow

Operating Efficiency

Strong Return On Equity

Consistent Revenue Growth

Consistent Operating Cash Flow Growth

Margin Improvement

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

BioSig Technologies

A-Score: 4.9/10

Value: 8.0

Growth: 6.9

Quality: 4.8

Yield: 0.0

Momentum: 10.0

Volatility: 0.0

1-Year Total Return ->

Nevro

A-Score: 4.7/10

Value: 9.2

Growth: 4.7

Quality: 4.3

Yield: 0.0

Momentum: 7.5

Volatility: 2.3

1-Year Total Return ->

ClearPoint Neuro

A-Score: 4.2/10

Value: 6.0

Growth: 4.4

Quality: 4.1

Yield: 0.0

Momentum: 9.5

Volatility: 1.0

1-Year Total Return ->

NeuroOne Medical Technologies

A-Score: 3.7/10

Value: 6.8

Growth: 6.1

Quality: 4.2

Yield: 0.0

Momentum: 4.0

Volatility: 1.3

1-Year Total Return ->

Accelerate Diagnostics

A-Score: 3.5/10

Value: 10.0

Growth: 5.6

Quality: 5.0

Yield: 0.0

Momentum: 0.0

Volatility: 0.3

1-Year Total Return ->

Cytek Biosciences

A-Score: 3.4/10

Value: 6.3

Growth: 7.0

Quality: 3.8

Yield: 0.0

Momentum: 1.5

Volatility: 2.0

1-Year Total Return ->

Peers Metrics

12.e Scoring ^Insights

12.f DCF ^BETA

Parameters

Short Term Growth

13.11%

Short term Time

10.0

Long-Term Growth

2.00%

WACC

6.62%

Accelerate Diagnostics, Inc. - US00430H2013

1. Company Snapshot

1.a. Company Description

1.b. Last Insights on AXDX

1.c. Company Highlights

Weak Momentum

Cheaper

Medium Volatility

Earnings Miss

Revenues Miss

More Volatile

Earnings Beats

Fairly Valued

Stable Momentum

Average Yield

Strong Momentum

2. Transcript Summary

3. NewsRoom

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (10.47%)

6. Segments

Accelerate Pheno

Expected Growth: 10.47%

Other

Expected Growth: 8.27%

7. Detailed Products

Accelerate Pheno

Accelerate PhenoTest BC Kit

Accelerate Arc Module

8. Accelerate Diagnostics, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Bargaining Power Of Customers

Bargaining Power Of Suppliers

Threat Of New Entrants

Intensity Of Rivalry

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

11. Quality Control: Accelerate Diagnostics, Inc. passed 3 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

0.03$

Current Price

0.03$

Potential

-0.00%

Expected Cash-Flows

12.e Scoring ^Insights

12.f DCF ^BETA